Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

18.28 -0.43 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharma

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Earns $10 Million Phase 1 Milestone Payment
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals, inc (ARWR) Q3 2021 Earnings Call Transcript
ARWR earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Arrowhead Pharmaceuticals Q3 Earnings
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08%... 
Via Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals: Buy the Dip?
This biotech underdog offers more than meets the eye. 
Via The Motley Fool
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Russell 2000 Traders Place Bearish Bets Via IWM ETF
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM... 
Via Benzinga
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: 
Via Benzinga
Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell... 
Via Benzinga
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to 4,348.47. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
56 Biggest Movers From Friday
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 73.2% to close at $18.79. A 13G... 
Via Benzinga
S&P 500 Logs Another Record High as "Fear Gauge" Dips
Stocks are modestly in the black midday, thanks to upbeat monthly jobs data that showed 850,000 jobs were added in June. 
Via Talk Markets
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million... 
Via Benzinga
Arrowhead Stock Plunges, Alector Stock Surges On Drug News
Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged. 
Via Investor's Business Daily
Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to 4,340.12. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
A paused clinical trial with an important asset wasn't what investors wanted to hear today. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.